Amit Sabnis, MD

Title(s)Assistant Professor, Pediatrics
SchoolSchool of Medicine
Address1550 Fourth Street, #384E
San Francisco CA 94158
ORCID ORCID Icon0000-0002-2061-5139 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoCert2007 Medicine (Certificate in Biomedical Research)
    University of California, San FranciscoM.D.2008 School of Medicine
    University of California, San Francisco Residency 2011Pediatrics
    University of California, San FranciscoFellowship2014Pediatric Hematology-Oncology
    University of California, San Francisco, CA2019Diversity, Equity, and Inclusion Champion Training

    Collapse Overview 
    Collapse Overview
    I am a pediatric oncologist and physician-scientist with a focus on examining new therapeutic strategies for sarcomas. Whether using genetic and biochemical tools for discovery, preclinical models for target and biomarker validation, or participating in the care of patients on clinical trials, my goal is to align my research and clinical practice to improve cure rates and quality of life for these patients.

    Collapse Research 
    Collapse Research Activities and Funding
    Defining and targeting ER quality control dependence in rhabdomyosarcoma
    NIH K08CA218691Jul 16, 2018 - Jun 30, 2023
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO Precis Oncol. 2024 Jun; 8:e2400103. Vo KT, Sabnis AJ, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey B, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Jaju A, Fox E, Weigel BJ, Hawkins DS, Mooney MM, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW. PMID: 38935895.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    2. Abstract 1759: Integrative longitudinal genomic analysis of therapy-resistant and metastatic pediatric cancers. Cancer Research. 2024 Mar 22; 84(6_Supplement):1759-1759. Martell MH, Shah SA, Lee LA, Leung LS, Cho CS, Ventura VM, Golla GA, Marinoff MA, Young YE, Tanasa TB, Behroozfard BI, Liu LH, Spillinger SA, Turski TM, Elzie-Tuttle EN, Espinosa-Mendez EC, Rangaswami RA, Cooney CT, Kline KC, Agrawal AA, Michlisch MJ, Stieglitz SE, Loh LM, Sabnis SA, Vo VK, Spunt SS, Lacayo LN, Beal BH, Hazard HF, Salama SS, Haussler HD, Vaske VO, Breese BM, Sweet-Cordero SE. .
      View in: Publisher Site   Mentions:
    3. Abstract 2862: Evolution of clinically relevant variants in advanced pediatric sarcomas. Cancer Research. 2024 Mar 22; 84(6_Supplement):2862-2862. Comeau CH, Vega VL, Church CA, Maese ML, Pinto PN, Macy MM, Applebaum AM, Sabnis SA, Kim KA, Colace CS, Dela Cruz DF, DuBois DS, Collins CN, Janeway JK. .
      View in: Publisher Site   Mentions:
    4. Abstract 138: UCHL5 and PAX3-FOXO1 resolve replication stress in rhabdomyosarcoma. Cancer Research. 2024 Mar 22; 84(6_Supplement):138-138. Sabnis SA, Sahu SP, Pan PY. .
      View in: Publisher Site   Mentions:
    5. The essential chaperone DNAJC17 activates HSP70 to coordinate RNA splicing and G2-M progression. bioRxiv. 2023 Oct 26. Allegakoen DV, Kwong K, Morales J, Bivona TG, Sabnis AJ. PMID: 37961102; PMCID: PMC10634838.
      View in: PubMed   Mentions:
    6. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precis Oncol. 2023 03; 7:e2200334. Marinoff AE, Spurr LF, Fong C, Li YY, Forrest SJ, Ward A, Doan D, Corson L, Mauguen A, Pinto N, Maese L, Colace S, Macy ME, Kim A, Sabnis AJ, Applebaum MA, Laetsch TW, Glade-Bender J, Weiser DA, Anderson M, Crompton BD, Meyers P, Zehir A, MacConaill L, Lindeman N, Nowak JA, Ladanyi M, Church AJ, Cherniack AD, Shukla N, Janeway KA. PMID: 36996377; PMCID: PMC10531050.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    7. GATOR2-dependent mTORC1 activity is a therapeutic vulnerability in FOXO1 fusion-positive rhabdomyosarcoma. JCI Insight. 2022 12 08; 7(23). Morales J, Allegakoen DV, Garcia JA, Kwong K, Sahu PK, Fajardo DA, Pan Y, Horlbeck MA, Weissman JS, Gustafson WC, Bivona TG, Sabnis AJ. PMID: 36282590; PMCID: PMC9746907.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    8. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. JCO Precis Oncol. 2022 11; 6:e2200390. Lazo De La Vega L, Comeau H, Sallan S, Al-Ibraheemi A, Gupta H, Li YY, Tsai HK, Kang W, Ward A, Church AJ, Kim A, Pinto NR, Macy ME, Maese LD, Sabnis AJ, Cherniack AD, Lindeman NI, Anderson ME, Cooney TM, Yeo KK, Reaman GH, DuBois SG, Collins NB, Johnson BE, Janeway KA, Forrest SJ. PMID: 36446043; PMCID: PMC9812632.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    9. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022 10 03; 24(10):1776-1789. Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A, Fox E. PMID: 35395680; PMCID: PMC9527518.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    10. Abstract A015: Biochemical and preclinical anti-tumor activity of a bi-steric mTORC1-selective inhibitor in fusion positive rhabdomyosarcoma. Clinical Cancer Research. 2022 Sep 15; 28(18_Supplement):a015-a015. Morales MJ, Kwong KK, Gustafson GW, Sabnis SA. .
      View in: Publisher Site   Mentions:
    11. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 08; 28(8):1581-1589. Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, Sabnis AJ, Weiser DA, Glade-Bender JL, Homans AC, Hipps J, Harris H, Manning D, Al-Ibraheemi A, Li Y, Gupta H, Cherniack AD, Lo YC, Strand GR, Lee LA, Pinches RS, Lazo De La Vega L, Harden MV, Lennon NJ, Choi S, Comeau H, Harris MH, Forrest SJ, Clinton CM, Crompton BD, Kamihara J, MacConaill LE, Volchenboum SL, Lindeman NI, Van Allen E, DuBois SG, London WB, Janeway KA. PMID: 35739269; PMCID: PMC10953704.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    12. Addition of chemo-immunotherapy to standard induction chemotherapy for high-risk neuroblastoma. Journal of Clinical Oncology. 2022 Jun 1; 40(16_suppl):e22009-e22009. Fernandez FK, Sabnis SA, Titapiwatanakun TR, Baker BK, Tcheng TW. .
      View in: Publisher Site   Mentions:
    13. Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J). Journal of Clinical Oncology. 2022 Jun 1; 40(16_suppl):3009-3009. Vo VK, Sabnis SA, Williams WP, Roy-Chowdhuri RS, Patton PD, Coffey CB, Reid RJ, Piao PJ, Saguilig SL, Alonzo AT, Berg BS, Jaju JA, Fox FE, Hawkins HD, Mooney MM, Takebe TN, Tricoli TJ, Janeway JK, Seibel SN, Parsons PD. .
      View in: Publisher Site   Mentions:
    14. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021; 5. Schienda J, Church AJ, Corson LB, Decker B, Clinton CM, Manning DK, Imamovic-Tuco A, Reidy D, Strand GR, Applebaum MA, Bagatell R, DuBois SG, Glade-Bender JL, Kang W, Kim A, Laetsch TW, Macy ME, Maese L, Pinto N, Sabnis AJ, Schiffman JD, Colace SI, Volchenboum SL, Weiser DA, Nowak JA, Lindeman NI, Janeway KA, Crompton BD, Kamihara J. PMID: 34964003; PMCID: PMC8710335.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    15. Clinical characteristics and outcomes of infants compared with children diagnosed with rhabdomyosarcoma: Analysis of surveillance, epidemiology and end results data from 2000 to 2016. Cancer Rep (Hoboken). 2022 05; 5(5):e1503. Rees HD, Hills NK, Sabnis AJ, Tulpule AB, Shimotake TK, Goldsby RE. PMID: 34254742; PMCID: PMC9124517.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    16. Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):10005-10005. Church CA, Corson CL, Kao KP, Imamovic-Tuco IA, Kang KW, Pinto PN, Maese ML, Laetsch LT, Kim KA, Colace CS, Macy MM, Applebaum AM, Bagatell BR, Sabnis SA, Weiser WD, Glade Bender GJ, Volchenboum VS, DuBois DS, London LW, Janeway JK. .
      View in: Publisher Site   Mentions:
    17. HGG-01. ENTRECTINIB IN RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS: UPDATED DATA IN CHILDREN AND ADOLESCENTS. Neuro-Oncology. 2020 Dec 4; 22(Suppl 3):iii344-iii344. Robinson RG, Desai DA, Basu BE, Foster FJ, Gauvain GK, Sabnis SA, Shusterman SS, Macy MM, Mease ML, Yoon YJ, Cash CT, Abdelbaki AM, Nazemi NK, Pratilas PC, Weiss WB, Chohan CS, Cardenas CA, Hutchinson HK, Bergthold BG, Gajjar GA. .
      View in: Publisher Site   Mentions:
    18. Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access. Blood. 2020 Nov 5; 136(Supplement 1):23-24. Tarlock TK, Meshinchi MS, Rubnitz RJ, Karol KS, Spitzer SB, Sabnis SA, Pathan PA, Messahel MB. .
      View in: Publisher Site   Mentions:
    19. Outcomes of Elderly Patients with Soft Tissue Sarcoma of the Extremities. International Journal of Radiation Oncology • Biology • Physics. 2020 Nov 1; 108(3):e6. Chew CJ, Lloyd LS, Okimoto OR, Sabnis SA, Nakakura NE, Corvera CC, Zimel ZM, Horvai HA, Cho CS, Wustrack WR, Gottschalk GA, O'Donnell OR, Jahan JT, Braunstein BS. .
      View in: Publisher Site   Mentions:
    20. Germline MUTYH Mutation in a Pediatric Cancer Survivor Developing a Secondary Malignancy. J Pediatr Hematol Oncol. 2020 10; 42(7):e647-e654. Lavergne V, Sabnis A, Tupule A, Davidson PR, Kline C, Matthay K, Nicolaides T, Goldsby R, Braunstein S, Fogh SE, Sneed PK, Menzel P, Nakamura A, DuBois SG, Haas-Kogan DA, Nakamura JL. PMID: 31815884.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    21. Abstract B13: Leveraging cloud-based computational resources for gene fusion discovery with potential clinical implications for pediatric solid tumor patients. Cancer Research. 2020 Jul 15; 80(14_Supplement):b13-b13. Imamovic IA, Church CA, Corson CL, Reidy RD, Pinto PN, Maese ML, Laetsch LT, Kim KA, Vear VS, Macy MM, Applebaum AM, Bagatell BR, Sabnis SA, Weiser WD, Glade-Bender GJ, Strand SG, Lee LL, Pinches PR, Clinton CC, Crompton CB, Lindeman LN, DuBois DS, Janeway JK, Van Allen VE. .
      View in: Publisher Site   Mentions:
    22. Abstract A06: The added value of examining germline variants in a precision cancer therapy study. Cancer Research. 2020 Jul 15; 80(14_Supplement):a06-a06. Schienda SJ, Clinton CC, Corson CL, Imamovic-Tuco IA, Pinto PN, Maese ML, Laetsch LT, Kim KA, Vear VS, Macy MM, Applebaum AM, Bagatell BR, Sabnis SA, Weiser WD, Glade-Bender GJ, Volchenboum VS, Kang KW, Manning MD, Nowak NJ, Schiffman SJ, Lindeman LN, Church CA, Janeway JK, Crompton CB, Kamihara KJ. .
      View in: Publisher Site   Mentions:
    23. Abstract A27: An apoptosis-based screen for targeted agents in rhabdomyosarcoma reveals potential combination therapies. Cancer Research. 2020 Jul 15; 80(14_Supplement):a27-a27. Sabnis SA, Chen CS, Morales MC, Braun BB. .
      View in: Publisher Site   Mentions:
    24. Abstract A59: Sequencing identifies diagnostically relevant alterations in pediatric solid tumor patients. Cancer Research. 2020 Jul 15; 80(14_Supplement):a59-a59. Church CA, Corson CL, Imamovic-Tuco IA, Strand SG, Reidy RD, Doan DD, Pinches PR, Applebaum AM, Bagatell BR, Crompton CB, DuBois DS, Bender BJ, Laetsch LT, Lee LL, Lindeman LN, Harris HM, Macy MM, Maese ML, Pinto PN, Sabnis SA, Van Allen VE, Vear VS, Weiser WD, Clinton CC, Janeway JK. .
      View in: Publisher Site   Mentions:
    25. Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):107-107. Desai DA, Robinson RG, Basu BE, Foster FJ, Gauvain GK, Sabnis SA, Shusterman SS, Macy MM, Maese ML, Yoon YJ, Cash CT, Abdelbaki AM, Nazemi NK, Weiss WB, Chohan CS, Cardenas CA, Hutchinson HK, Bergthold BG, Gajjar GA, Fox FE. .
      View in: Publisher Site   Mentions:
    26. PDCT-13. ENTRECTINIB IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS. Neuro-Oncology. 2019 Nov 11; 21(Supplement_6):vi186-vi186. Robinson RG, Desai DA, Gauvain GK, Basu BE, Dorris DK, Maese ML, Sabnis SA, Foster FJ, Shusterman SS, Yoon YJ, Weiss WB, Abdelbaki AM, Farid-Kapadia FM, Meneses-Lorente MG, Cardenas CA, Hutchinson HK, Bergthold BG, Chow Maneval CE, Fox FE, Gajjar GA. .
      View in: Publisher Site   Mentions:
    27. Use of three-dimensional printing and intraoperative navigation in the surgical resection of metastatic acetabular osteosarcoma. BMJ Case Rep. 2019 Sep 30; 12(9). Heunis JC, Cheah JW, Sabnis AJ, Wustrack RL. PMID: 31570349; PMCID: PMC6768338.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    28. Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers. Cell Rep. 2019 08 27; 28(9):2317-2330.e8. Chatterjee N, Pazarentzos E, Mayekar MK, Gui P, Allegakoen DV, Hrustanovic G, Olivas V, Lin L, Verschueren E, Johnson JR, Hofree M, Yan JJ, Newton BW, Dollen JV, Earnshaw CH, Flanagan J, Chan E, Asthana S, Ideker T, Wu W, Suzuki J, Barad BA, Kirichok Y, Fraser JS, Weiss WA, Krogan NJ, Tulpule A, Sabnis AJ, Bivona TG. PMID: 31461649; PMCID: PMC6728083.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    29. Abstract 3104: A high prevalence of chromosomal translocations as drivers in high-risk pediatric solid cancers. Cancer Research. 2019 Jul 1; 79(13_Supplement):3104-3104. Corson CL, Imamovic-Tuco IA, Strand SG, Reidy RD, Doan DD, Applebaum AM, Bagatell BR, Crompton CB, DuBois DS, Bender BJ, Kim KA, Laetsch LT, Lee LL, Lindeman LN, MacConaill ML, Macy MM, Maese ML, Pinches PS, Pinto PN, Sabnis SA, Allen AE, Vear VS, Weiser WD, Clinton CC, Janeway JK, Church CA. .
      View in: Publisher Site   Mentions:
    30. Abstract 2664: Differential activation of the integrated stress response correlates with anti-tumor activity of imipridones ONC201 and ONC206 in pediatric sarcomas. Molecular and Cellular Biology / Genetics. 2019 Jul 1; 2664-2664. Allegakoen AD, Tarapore TR, Allen AJ, Sabnis SA, Bivona BT. .
      View in: Publisher Site   Mentions:
    31. Abstract 3656: The mTOR-activating GATOR2 complex is essential in PAX3-FOXO1- positive rhabdomyosarcoma. Tumor Biology. 2019 Jul 1; 3656-3656. Sabnis SA, Allegakoen AD, Bivona BT. .
      View in: Publisher Site   Mentions:
    32. Abstract 4268: Protein folding pathway modulation upon Hsp70 inhibition in cancer cells. Molecular and Cellular Biology / Genetics. 2019 Jul 1; 4268-4268. Sannino SS, Guerriero GC, Sabnis SA, Bridsky BJ. .
      View in: Publisher Site   Mentions:
    33. Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors. Journal of Clinical Oncology. 2019 May 20; 37(15_suppl):10009-10009. Robinson RG, Gajjar GA, Gauvain GK, Basu BE, Macy MM, Maese ML, Sabnis SA, Foster FJ, Shusterman SS, Yoon YJ, Weiss WB, Abdelbaki AM, Farid-Kapadia FM, Meneses-Lorente MG, Cardenas CA, Hutchinson HK, Bergthold BG, Chow Maneval CE, Fox FE, Desai DA. .
      View in: Publisher Site   Mentions:
    34. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends Mol Med. 2019 03; 25(3):185-197. Sabnis AJ, Bivona TG. PMID: 30686761; PMCID: PMC6401263.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansAnimalsCells
    35. Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci. 2018 09 05; 131(17). Sannino S, Guerriero CJ, Sabnis AJ, Stolz DB, Wallace CT, Wipf P, Watkins SC, Bivona TG, Brodsky JL. PMID: 30131440; PMCID: PMC6140321.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    36. Abstract 2325: Protein homeostasis adaptation to Hsp70 inhibition in cancer. Molecular and Cellular Biology / Genetics. 2018 Jul 1; 2325-2325. Sannino SS, Guerriero GC, Sabnis SA, Bivona BT, Brodsky BJ. .
      View in: Publisher Site   Mentions:
    37. Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors. Journal of Clinical Oncology. 2018 May 20; 36(15_suppl):10536-10536. Desai DA, Brodeur BG, Foster FJ, Berg BS, Basu BE, Shusterman SS, Sabnis SA, Macy MM, Yoon YJ, Gauvain GK, Esquibel EV, Chow Maneval CE, Multani MP, Fox FE. .
      View in: Publisher Site   Mentions:
    38. EWSR1-NFATC2 gene fusion in a soft tissue tumor with epithelioid round cell morphology and abundant stroma: a case report and review of the literature. Hum Pathol. 2018 11; 81:281-290. Cohen JN, Sabnis AJ, Krings G, Cho SJ, Horvai AE, Davis JL. PMID: 29626598; PMCID: PMC8104452.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    39. Reducing Second Gram-Negative Antibiotic Therapy on Pediatric Oncology and Hematopoietic Stem Cell Transplantation Services. Infect Control Hosp Epidemiol. 2017 09; 38(9):1039-1047. Wattier RL, Levy ER, Sabnis AJ, Dvorak CC, Auerbach AD. PMID: 28758610.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    40. Abstract CT030: STARTRK-NG: A phase 1/1b study of entrectinib in children and adolescents with advanced solid tumors and primary CNS tumors, with or without TRK, ROS1, or ALK fusions. Clinical Trials. 2017 Jul 1; ct030-ct030. Desai DA, Brodeur BG, Foster FJ, Shusterman SS, Sabnis SA, Macy MM, Wetmore WC, Basu BE, Hornby HZ, Esquibel EV, Maneval ME, Multani MP, Fox FE. .
      View in: Publisher Site   Mentions:
    41. HSP70 dependence in rhabdomyosarcoma: Seed or soil? Cell Cycle. 2017 01 17; 16(2):147-148. Sabnis AJ, Bivona TG. PMID: 27686974; PMCID: PMC5283818.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    42. Combined chemical-genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcoma. Proc Natl Acad Sci U S A. 2016 08 09; 113(32):9015-20. Sabnis AJ, Guerriero CJ, Olivas V, Sayana A, Shue J, Flanagan J, Asthana S, Paton AW, Paton JC, Gestwicki JE, Walter P, Weissman JS, Wipf P, Brodsky JL, Bivona TG. PMID: 27450084; PMCID: PMC4987817.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    43. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. PMID: 26301689; PMCID: PMC4734742.
      View in: PubMed   Mentions: 144     Fields:    Translation:HumansCells
    44. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. PMID: 25665005; PMCID: PMC4930244.
      View in: PubMed   Mentions: 285     Fields:    Translation:HumansAnimalsCells
    45. Neurologic Emergencies. Supportive Care in Pediatric Oncology. 2015 Jan 1; 71-96. Sabnis SA, Finlay FJ, Mueller MS. .
      View in: Publisher Site   Mentions:
    46. Activating mutations cluster in the "molecular brake" regions of protein kinases and do not associate with conserved or catalytic residues. Hum Mutat. 2014 Mar; 35(3):318-28. Molina-Vila MA, Nabau-Moretó N, Tornador C, Sabnis AJ, Rosell R, Estivill X, Bivona TG, Marino-Buslje C. PMID: 24323975.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    47. FGFR fusions in the driver's seat. Cancer Discov. 2013 Jun; 3(6):607-9. Sabnis AJ, Bivona TG. PMID: 23749526; PMCID: PMC4988530.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    48. JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal. Cancer Cell. 2009 Apr 07; 15(4):341-52. Santaguida M, Schepers K, King B, Sabnis AJ, Forsberg EC, Attema JL, Braun BS, Passegué E. PMID: 19345332; PMCID: PMC2669108.
      View in: PubMed   Mentions: 73     Fields:    Translation:AnimalsCells
    49. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol. 2009 Mar 17; 7(3):e59. Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS. PMID: 19296721; PMCID: PMC2656550.
      View in: PubMed   Mentions: 53     Fields:    Translation:AnimalsCells
    50. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet. 2008 Aug; 40(8):963-70. McGowan KA, Li JZ, Park CY, Beaudry V, Tabor HK, Sabnis AJ, Zhang W, Fuchs H, de Angelis MH, Myers RM, Attardi LD, Barsh GS. PMID: 18641651; PMCID: PMC3979291.
      View in: PubMed   Mentions: 192     Fields:    Translation:HumansAnimalsCells
    51. Leukemogenic K-RasG12D Induces Cell Cycle Entry and Clonal Dominance in Hematopoietic Stem Cells. Blood. 2007 Nov 16; 110(11):778-778. Sabnis SA, Cheung CL, Shannon SK, Braun BB. .
      View in: Publisher Site   Mentions:
    52. Multiparameter Flow Cytometric Analysis Reveals Aberrant Phosphorylation of a Network of Effector Molecules in Defined Populations of Kras Mutant Bone Marrow. Blood. 2005 Nov 16; 106(11):239-239. Van Meter VM, Diaz-Flores DE, Archard AJ, Kotecha KN, Sabnis SA, Irish IJ, Nolan NG, Shannon SK, Braun BB. .
      View in: Publisher Site   Mentions:
    Amit's Networks
    Concepts (172)
    Derived automatically from this person's publications.
    _
    Co-Authors (38)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _